Morphic Therapeutic racks up $51.5 mln Series A
Waltham, Massachusetts-based Morphic Therapeutic, a biotechnology company focused on developing oral integrin drugs, has closed $51.5 million in Series A financing. SR One and Pfizer Venture Investments led the round with participation from other investors that included Omega Funds and AbbVie Ventures.
30 June 2016•1 min read
